Baxter must divest Autoplex T Factor VIII inhibitor -- FTC proposed consent agreement for Immuno merger.
Executive Summary
BAXTER MUST DIVEST AUTOPLEX T FACTOR VIII INHIBITOR BY APRIL to a Federal Trade Commission-approved buyer under a proposed consent agreement between FTC and Baxter International announced Dec. 19. The agreement resolves antitrust concerns raised by the commission over Baxter's proposed acquisition of Immuno.